Research Progress on the Regulation of Chronic Metabolic Diseases by Paracrine Fibroblast Growth Factors
10.11714/jsysu.med.YX20260077
- VernacularTitle:旁分泌成纤维细胞生长因子调控慢性代谢性疾病的研究进展
- Author:
Qing ZHANG
1
;
Haiyan LI
1
Author Information
1. Department of Medical Technology, Xi'an Medical University, Xi'an 710021, China
- Publication Type:Review
- Keywords:
chronic metabolic diseases;
glucose and lipid metabolic disorders;
paracrine fibroblast growth factors;
pathogenesis;
therapeutic target
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2026;47(5):788-798
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of chronic metabolic diseases, including obesity, type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD), continues to rise globally. Disordered glucose and lipid metabolism represents their common pathophysiological foundation. Secreted fibroblast growth factor (FGF) is key regulators of glucose and lipid homeostasis. Among them, the paracrine FGFs, mainly comprising FGF1, FGF2, FGF4, FGF6, FGF8, FGF9, FGF10, and FGF16, require systematic integration regarding their metabolic regulatory functions. This review elucidates the molecular structural characteristics of paracrine FGFs and their central regulatory roles in maintaining glucose and lipid homeostasis, covering their modulation of metabolic networks over multiple tissues and organs including, adipose tissue, liver, skeletal muscle, pancreatic islets, and the nervous system. Furthermore, the expression alterations and functional abnormalities of these factors in chronic metabolic diseases are summarized. This review aims to highlight the critical position of paracrine FGFs in the pathogenesis of metabolic diseases and to provide novel therapeutic targets and theoretical foundations for the prevention and treatment of disorders associated with glucolipid metabolic dysregulation.